Judith Falloon1, Fei Ji2, Craig Curtis3, Stephan Bart4, Eric Sheldon5, Diane Krieger5, Filip Dubovsky2, Stacie Lambert6, Therese Takas2, Tonya Villafana2, Mark T Esser2. 1. MedImmune, 1 Medimmune Way, Gaithersburg, MD 20878, United States. Electronic address: FalloonJ@MedImmune.com. 2. MedImmune, 1 Medimmune Way, Gaithersburg, MD 20878, United States. 3. Compass Research, 100 West Gore St. Suite 202, Orlando, FL 32806, United States. 4. Optimal Research, Optimal Sites, 14808 Physicians Lane, Suite 211, Rockville, MD 20850, United States. 5. Miami Research Associates, 6141 Sunset Dr., South Miami, FL 33143, United States. 6. MedImmune, 319 N Bernardo Ave., Mountain View, CA 94043, United States.
Abstract
BACKGROUND:Respiratory syncytial virus (RSV) causes significant illness in older adults resulting in substantial health and economic impact. A successful vaccine would reduce morbidity in this growing segment of the population. METHODS: In this double-blind phase 1 study, subjects 60 years of age and older were enrolled by cohort and randomized to receive vaccines containing escalating doses (20, 50, or 80μg) of soluble RSV fusion protein (sF) alone or adjuvanted with 2.5μg of glucopyranosyl lipid A, a toll-like receptor-4 agonist, in 2% stable emulsion (GLA-SE). Each cohort included 20 vaccine and 4 placebo recipients. Immune responses were evaluated using assays for RSV microneutralizing, anti-F IgG, and palivizumab competitive antibodies and for F-specific interferon (IFN)-γ enzyme-linked immunospot (ELISPOT) responses. RESULTS: The inclusion of adjuvant increased local reactogenicity, with the majority of subjects who received sF and adjuvant reporting low-grade injection site pain or tenderness. At all doses, the safety profile was acceptable for further development. Immune responses were antigen dose-dependent, and the inclusion of adjuvant increased both humoral and cellular immune responses, with responses statistically higher than for placebo recipients in all 4 assays. At the highest dosage level with adjuvant, half of the subjects had a ≥3-fold rise from day 0 in RSV neutralizing antibody titers, and all had a ≥3-fold rise in antibody levels by anti-F IgG and palivizumab competitive antibody assays on day 29. For the day 8 IFNγ ELISPOT assay, 74% of subjects in the highest dosing cohort had a ≥3-fold rise from baseline. CONCLUSIONS: The safety and immunogenicity results from this study support inclusion of the GLA-SE adjuvant in this RSV vaccine for older adults and also support assessment of the efficacy of the vaccine in a larger clinical trial. Clinicaltrials.gov NCT02115815.
RCT Entities:
BACKGROUND:Respiratory syncytial virus (RSV) causes significant illness in older adults resulting in substantial health and economic impact. A successful vaccine would reduce morbidity in this growing segment of the population. METHODS: In this double-blind phase 1 study, subjects 60 years of age and older were enrolled by cohort and randomized to receive vaccines containing escalating doses (20, 50, or 80μg) of soluble RSV fusion protein (sF) alone or adjuvanted with 2.5μg of glucopyranosyl lipid A, a toll-like receptor-4 agonist, in 2% stable emulsion (GLA-SE). Each cohort included 20 vaccine and 4 placebo recipients. Immune responses were evaluated using assays for RSV microneutralizing, anti-F IgG, and palivizumab competitive antibodies and for F-specific interferon (IFN)-γ enzyme-linked immunospot (ELISPOT) responses. RESULTS: The inclusion of adjuvant increased local reactogenicity, with the majority of subjects who received sF and adjuvant reporting low-grade injection site pain or tenderness. At all doses, the safety profile was acceptable for further development. Immune responses were antigen dose-dependent, and the inclusion of adjuvant increased both humoral and cellular immune responses, with responses statistically higher than for placebo recipients in all 4 assays. At the highest dosage level with adjuvant, half of the subjects had a ≥3-fold rise from day 0 in RSV neutralizing antibody titers, and all had a ≥3-fold rise in antibody levels by anti-F IgG and palivizumab competitive antibody assays on day 29. For the day 8 IFNγ ELISPOT assay, 74% of subjects in the highest dosing cohort had a ≥3-fold rise from baseline. CONCLUSIONS: The safety and immunogenicity results from this study support inclusion of the GLA-SE adjuvant in this RSV vaccine for older adults and also support assessment of the efficacy of the vaccine in a larger clinical trial. Clinicaltrials.gov NCT02115815.
Authors: Sara A Taleb; Asmaa A Al Thani; Khalid Al Ansari; Hadi M Yassine Journal: Eur J Clin Microbiol Infect Dis Date: 2018-06-06 Impact factor: 3.267
Authors: Claire M Midgley; Amber K Haynes; Jason L Baumgardner; Christina Chommanard; Sara W Demas; Mila M Prill; Glen R Abedi; Aaron T Curns; John T Watson; Susan I Gerber Journal: J Infect Dis Date: 2017-08-01 Impact factor: 5.226
Authors: Emilie Seydoux; Hong Liang; Natasha Dubois Cauwelaert; Michelle Archer; Nicholas D Rintala; Ryan Kramer; Darrick Carter; Christopher B Fox; Mark T Orr Journal: J Immunol Date: 2018-05-16 Impact factor: 5.422